GZR18 injection
Sponsors
Gan & Lee Pharmaceuticals.
Conditions
Obesity/OverweightObstructive Sleep Apnea (OSA)Overweight or ObesityType 2 Diabetes
Phase 1
A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects
Not yet recruitingNCT06974487
Start: 2025-05-08End: 2025-09-30Target: 30Updated: 2025-05-16
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
RecruitingNCT07141030
Start: 2025-04-11End: 2026-03-31Target: 32Updated: 2025-11-21
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function
RecruitingNCT07144098
Start: 2025-08-12End: 2027-01-26Target: 24Updated: 2025-08-27
Phase 3
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
RecruitingNCT07292441
Start: 2026-01-22End: 2027-10-01Target: 500Updated: 2026-03-11
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy
Not yet recruitingNCT07493057
Start: 2026-04-27End: 2027-11-14Target: 140Updated: 2026-03-27
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy
Not yet recruitingNCT07501832
Start: 2026-03-27End: 2028-09-28Target: 140Updated: 2026-04-03